Q1 Results 2026

“Core Reckitt delivered Q1 LFL net revenue growth of 1.3%, impacted by very low seasonal incidence, weak categories in Europe and geopolitical disruption. Excluding seasonal OTC, Core Reckitt delivered 3.1% growth.

This was led by high-single-digit growth in Emerging Markets, despite market-specific headwinds. We maintain our LFL net revenue guidance for 2026. This will be driven by sequential growth from our market-leading Powerbrands, as the season resets and we continue to launch superior innovations including Mucinex 12hr Cold and Fever, improved performance in Europe and continued strong growth across China, India and non-seasonal North America.”